$NMTC

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

NeuroOne Medical Technologies (NMTC) announced successful large-animal procedures using its StereoCED platform, enabling simultaneous drug delivery and electrophysiological recording. The company expects its first StereoCED revenue in fiscal Q4 2026, earlier than anticipated, and plans to launch human investigational clinical studies by the end of the quarter. The platform is not yet approved for commercial use.

NeuroOne Medical Technologies reported Q3 2026 revenue of $2.0M, up 16% YoY, with gross margin expanding to 59.9%. Product orders rose 43% YoY to $2.7M. Net loss increased to $2.0M. The company expects $9.2M-$10.5M revenue for fiscal 2026. Cash reserves totaled $2.0M. NeuroOne was added to the Russell Microcap Index. The stock is down 2.30%.

NeuroOne (NMTC) reported Q3 2026 product revenue of $2.0M, up 16% YoY. New orders reached $2.7M, with a $1.7M backlog. Full-year revenue guidance is $9.2M-$10.5M. Gross margin improved to 59.9%. Net loss was $2.0M, with non-GAAP EPS at -$0.28. Cash reserves declined to $2.0M. Management highlighted ISO 13485 certification for international expansion and upcoming regulatory milestones.

NeuroOne Medical Technologies reported Q3 2026 revenue up 16%, driven by demand for its OneRF Brain Ablation System, though recognized revenue was limited by manufacturing lead times. Gross margin rose to 59.9%. Management cited ISO 13485 certification, guidance of $9.2M to $10.5M for FY2026, and a second manufacturing site expected in early 2027.

NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. Product revenue rose 16% YoY to $2.0M and product gross margins expanded to 59.9%. New product orders were $2.7M, lifting backlog to $1.7M, and FY2026 orders totaled $11.2M. The company also cited ISO 13485 certification and updates on StereoCED and OneRF platforms.

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo

NeuroOne Medical Technologies (Nasdaq: NMTC) said it received ISO 13485-2016 certification for its quality management system covering design and development, manufacturing and distribution of electrosurgical generators and instruments, diagnostic neurophysiological devices, and related components. The company said the certification supports international commercialization of its Evo Cortical and Evo sEEG electrodes and OneRF Brain Ablation System, with Zimmer Biomet as distribution partner.

EQS-News: NeuroOne Medical Technologies / Key word(s): Science NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED Platform 30.07.2026 / 22:11 CET/CEST The issuer is solely responsible for the content of this announcement.

NeuroOne Medical Technologies (Nasdaq: NMTC) said physicians at Mayo Clinic Florida treated 25 drug-resistant focal epilepsy patients with the OneRF brain ablation system after SEEG monitoring. The company reported rare short-term effects, no serious long-term complications, reduced seizure frequency, and improved patient-reported quality of life, citing real-world experience.